Tomography News and Research

RSS

New Research Information on Tumor Necrosis Therapy

Researchers for Peregrine Pharmaceuticals presented today at the Strategic Research Institute’s Clinical-Stage Product Partnering Summit in La Jolla, CA a summary of clinical experience with Tumor Necrosis Therapy (TNT). The TNT technology is being developed in the U.S. and Europe by Peregrine under the trade name Cotara™. Over 200 patients have been treated with TNT world-wide and a TNT product has been approved to treat grade III or IV advanced lung cancer in the People’s Republic of China. A Cotara registration study for brain cancer has been approved by the U.S. Food and Drug Administration, and a Phase I colorectal cancer study is on-going at Stanford University Medical Center.

25 Mar 2004

£76 million research centre to make the UK a global centre of excellence for clinical imaging

GlaxoSmithKline (GSK) and Imperial College London today announce a unique research collaboration in medical imaging. GSK will contribute funding of £28m for the construction of a new Clinical Imaging Centre, next to Hammersmith Hospital in West London, UK. Research will focus on cancer, stroke, neurological diseases such as Parkinson's and multiple sclerosis and psychiatric diseases. In association with the Clinical Imaging Centre, GSK and Imperial have entered into a 10-year research agreement for medical imaging.

22 Mar 2004